HK1061678A1 - Pyridazinone aldose reductase inhibitors. - Google Patents

Pyridazinone aldose reductase inhibitors.

Info

Publication number: HK1061678A1
Authority: HK; Hong Kong
Prior art keywords: reductase inhibitors; aldose reductase; pyridazinone aldose; pyridazinone; inhibitors
Prior art date: 2001-03-30

Application number

HK04104538A

Other languages

English (en)

Inventor

Banavara Lakshman Mylari

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-30

Filing date

2004-06-24

Publication date

2004-09-30

2004-06-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-09-30 Publication of HK1061678A1 publication Critical patent/HK1061678A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

HK04104538A 2001-03-30 2004-06-24 Pyridazinone aldose reductase inhibitors. HK1061678A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28005101P	2001-03-30	2001-03-30
PCT/IB2002/000320 WO2002079198A1 (en)	2001-03-30	2002-01-31	Pyridazinone aldose reductase inhibitors

Publications (1)

Publication Number	Publication Date
HK1061678A1 true HK1061678A1 (en)	2004-09-30

Family

ID=23071435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK04104538A HK1061678A1 (en)	2001-03-30	2004-06-24	Pyridazinone aldose reductase inhibitors.

Country Status (44)

Country	Link
US (2)	US6579879B2 (xx)
EP (3)	EP1491540B1 (xx)
JP (1)	JP2004528319A (xx)
KR (1)	KR100586138B1 (xx)
CN (1)	CN1215067C (xx)
AP (1)	AP2002002461A0 (xx)
AR (1)	AR035798A1 (xx)
AT (3)	ATE348100T1 (xx)
AU (1)	AU2002226634B2 (xx)
BG (1)	BG108179A (xx)
BR (1)	BR0208571A (xx)
CA (1)	CA2442476A1 (xx)
CZ (1)	CZ20032563A3 (xx)
DE (3)	DE60216823T2 (xx)
DK (2)	DK1491540T3 (xx)
EA (1)	EA006023B1 (xx)
EC (1)	ECSP034671A (xx)
EE (1)	EE200300470A (xx)
ES (2)	ES2274369T3 (xx)
GE (1)	GEP20053675B (xx)
HK (1)	HK1061678A1 (xx)
HR (1)	HRP20030752A2 (xx)
HU (1)	HUP0303644A3 (xx)
IL (1)	IL156462A0 (xx)
IS (3)	IS2205B (xx)
MA (1)	MA27003A1 (xx)
MX (1)	MXPA03008850A (xx)
MY (1)	MY134304A (xx)
NO (1)	NO20034345L (xx)
NZ (1)	NZ528406A (xx)
OA (1)	OA12453A (xx)
PA (1)	PA8541801A1 (xx)
PE (1)	PE20030007A1 (xx)
PL (1)	PL365294A1 (xx)
PT (2)	PT1491540E (xx)
SI (1)	SI1373259T1 (xx)
SK (1)	SK11852003A3 (xx)
TN (1)	TNSN02037A1 (xx)
TW (1)	TWI245762B (xx)
UA (1)	UA73236C2 (xx)
UY (1)	UY27237A1 (xx)
WO (1)	WO2002079198A1 (xx)
YU (1)	YU71403A (xx)
ZA (1)	ZA200304671B (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL126999A (en)	1996-07-24	2002-03-10	Warner Lambert Co	Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
DE60204611T2 (de) *	2001-02-28	2006-05-11	Pfizer Products Inc., Groton	Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren
JP2004528319A (ja) *	2001-03-30	2004-09-16	ファイザー・プロダクツ・インク	ピリダジノンアルドースレダクダーゼ阻害物質
AU761191B2 (en) *	2001-05-24	2003-05-29	Pfizer Products Inc.	Therapies for tissue damage resulting from ischemia
RU2278116C2 (ru)	2002-01-09	2006-06-20	Пфайзер Продактс Инк.	Способ и промежуточные продукты для получения пиридазиноновых антидиабетических средств
US7419981B2 (en) *	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) *	2002-08-15	2004-05-13	Field Mark John	Synergistic combinations
US6872833B2 (en) *	2003-04-14	2005-03-29	Hoffmann-La Roche Inc.	Adenosine receptor ligands
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
AR049384A1 (es)	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
ES2282062T1 (es)	2004-06-04	2007-10-16	Teva Pharmaceutical Industries Ltd.	Composicion farmaceutica que contiene irbesartan.
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006028565A2 (en) *	2004-06-30	2006-03-16	Whitehead Institute For Biomedical Research	Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
AU2007206016A1 (en) *	2006-01-13	2007-07-26	Wyeth	Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
RS53230B (en)	2006-06-27	2014-08-29	Takeda Pharmaceutical Company Limited	CONDENSED CYCLICAL UNITS AS GPR40 RECEPTOR MODULATORS
WO2008070496A2 (en)	2006-12-01	2008-06-12	Bristol-Myers Squibb Company	N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US8173645B2 (en) *	2007-03-21	2012-05-08	Takeda San Diego, Inc.	Glucokinase activators
SG176464A1 (en)	2008-05-09	2011-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
WO2011071995A2 (en)	2009-12-08	2011-06-16	Case Western Reserve University	Compounds and methods of treating ocular disorders
US8916563B2 (en)	2010-07-16	2014-12-23	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and uses thereof
AU2012308243B2 (en) *	2011-09-15	2017-09-14	Taipei Medical University	Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
US9339542B2 (en) *	2013-04-16	2016-05-17	John L Couvaras	Hypertension reducing composition
RU2618628C1 (ru)	2013-04-17	2017-05-05	Пфайзер Инк.	Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний
CN103739547B (zh) *	2014-01-03	2015-09-02	沈阳药科大学	2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
US20180118756A1 (en) *	2015-04-14	2018-05-03	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase activity
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
SI3352754T1 (sl)	2016-06-21	2021-03-31	The Trustees Of Columbia University In The City Of New York	Zaviralci aldozne reduktaze in postopki njihove uporabe
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
US11690847B2 (en)	2016-11-30	2023-07-04	Case Western Reserve University	Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
JP2020514323A (ja)	2017-02-06	2020-05-21	ケースウエスタンリザーブユニバーシティ	短鎖デヒドロゲナーゼ活性を調節する組成物と方法
PL3658142T3 (pl)	2017-07-28	2024-08-26	Applied Therapeutics, Inc.	Związki i sposoby leczenia galaktozemii
CA3125765A1 (en)	2019-01-18	2020-07-23	Astrazeneca Ab	Pcsk9 inhibitors and methods of use thereof
CN113966396A (zh)	2019-05-07	2022-01-21	迈阿密大学	遗传性神经病和相关障碍的治疗和检测
MX2021014443A (es)	2019-05-31	2022-01-06	Ikena Oncology Inc	Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
BR112021024224A2 (pt)	2019-05-31	2022-04-26	Ikena Oncology Inc	Inibidores de tead e usos dos mesmos
WO2022120353A1 (en) *	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE47592B1 (en)	1977-12-29	1984-05-02	Ici Ltd	Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en)	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
US4996204A (en)	1989-05-11	1991-02-26	Pfizer Inc.	Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1992009594A1 (en) *	1990-11-30	1992-06-11	Tsumura & Co.	Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
EP0582643A1 (en)	1991-03-28	1994-02-16	Pfizer Inc.	Pyridazinone acetic acids
US5834466A (en)	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TWI238064B (en)	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP0003647A3 (en) *	1997-09-24	2002-12-28	Orion Corp	Bisethers of 1-oxa, aza and thianaphthalen-2-ones, their use for producing medicaments, the medicaments and their intermediates
FR2822827B1 (fr) *	2001-03-28	2003-05-16	Sanofi Synthelabo	Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
JP2004528319A (ja) *	2001-03-30	2004-09-16	ファイザー・プロダクツ・インク	ピリダジノンアルドースレダクダーゼ阻害物質
JP2004528344A (ja) *	2001-04-30	2004-09-16	ファイザー・プロダクツ・インク	アルドースレダクターゼ阻害薬とシクロオキシゲナーゼ−２阻害薬の併用
RU2278116C2 (ru) *	2002-01-09	2006-06-20	Пфайзер Продактс Инк.	Способ и промежуточные продукты для получения пиридазиноновых антидиабетических средств

2002
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-01-31 EP EP04023149A patent/EP1491540B1/en not_active Expired - Lifetime
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/en active IP Right Grant
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active IP Right Cessation
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 EP EP02716247A patent/EP1373259B1/en not_active Expired - Lifetime
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 CA CA002442476A patent/CA2442476A1/en not_active Abandoned
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 EP EP04023150A patent/EP1491541B1/en not_active Expired - Lifetime
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
2004
- 2004-06-24 HK HK04104538A patent/HK1061678A1/xx not_active IP Right Cessation
2006
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown

Also Published As

Publication number	Publication date
CA2442476A1 (en)	2002-10-10
DK1373259T3 (da)	2005-03-29
DE60217930T2 (de)	2007-10-18
DE60216823T2 (de)	2007-10-04
WO2002079198A1 (en)	2002-10-10
US6579879B2 (en)	2003-06-17
ES2231681T3 (es)	2005-05-16
CN1500087A (zh)	2004-05-26
EA006023B1 (ru)	2005-08-25
IS6845A (is)	2003-06-16
AP2002002461A0 (en)	2002-06-30
ATE348100T1 (de)	2007-01-15
SK11852003A3 (sk)	2004-07-07
YU71403A (sh)	2006-05-25
TNSN02037A1 (fr)	2005-12-23
EA200300673A1 (ru)	2003-12-25
UA73236C2 (en)	2005-06-15
OA12453A (en)	2006-05-24
EP1373259B1 (en)	2004-12-29
IS8251A (is)	2006-01-23
NO20034345D0 (no)	2003-09-29
EP1491541A1 (en)	2004-12-29
ATE286049T1 (de)	2005-01-15
TWI245762B (en)	2005-12-21
IL156462A0 (en)	2004-01-04
EP1491541B1 (en)	2007-01-24
DE60202452C5 (de)	2006-11-23
UY27237A1 (es)	2002-12-31
IS8250A (is)	2006-01-23
PE20030007A1 (es)	2003-01-28
US20030162784A1 (en)	2003-08-28
EP1491540A1 (en)	2004-12-29
AU2002226634B2 (en)	2007-01-25
PT1373259E (pt)	2005-03-31
MY134304A (en)	2007-12-31
DE60202452T2 (de)	2006-02-09
AR035798A1 (es)	2004-07-14
ECSP034671A (es)	2003-08-29
KR100586138B1 (ko)	2006-06-07
PT1491540E (pt)	2007-01-31
BG108179A (en)	2004-09-30
GEP20053675B (en)	2005-11-25
EE200300470A (et)	2004-02-16
BR0208571A (pt)	2004-03-23
DK1491540T3 (da)	2007-03-26
ES2274369T3 (es)	2007-05-16
US6849629B2 (en)	2005-02-01
EP1491540B1 (en)	2006-12-13
JP2004528319A (ja)	2004-09-16
ZA200304671B (en)	2004-06-25
MA27003A1 (fr)	2004-12-20
DE60217930D1 (de)	2007-03-15
HUP0303644A2 (hu)	2004-03-01
MXPA03008850A (es)	2003-12-04
ATE352551T1 (de)	2007-02-15
PL365294A1 (en)	2004-12-27
KR20030088484A (ko)	2003-11-19
SI1373259T1 (en)	2005-04-30
DE60202452D1 (de)	2005-02-03
NO20034345L (no)	2003-09-29
CZ20032563A3 (cs)	2004-05-12
DE60216823D1 (de)	2007-01-25
PA8541801A1 (es)	2002-10-28
HUP0303644A3 (en)	2008-06-30
HRP20030752A2 (en)	2005-06-30
EP1373259A1 (en)	2004-01-02
IS2205B (is)	2007-02-15
NZ528406A (en)	2004-03-26
US20020143017A1 (en)	2002-10-03
CN1215067C (zh)	2005-08-17

Publication	Publication Date	Title
HK1061678A1 (en)	2004-09-30	Pyridazinone aldose reductase inhibitors.
MXPA03007310A (es)	2003-12-04	Derivados de ftalazinona piperidino como inhibidores pde4.
MXPA03008177A (es)	2003-12-12	Inhibidores de metaloproteinasa..
MXPA03008180A (es)	2003-12-12	Inhibidores de metaloproteinasa.
MXPA03007166A (es)	2003-11-18	Pirido-pirimidinas 6-sustituidas.
MXPA03009647A (es)	2004-01-29	Heterociclildicarbamidas como inhibidores de caspasa.
MXPA03008183A (es)	2003-12-12	Inhibidores de metaloproteinasa.
GB2406009B (en)	2005-11-23	Amplifier
IL158099A0 (en)	2004-03-28	Amplifier
MXPA03006603A (es)	2004-02-12	Agonista de subtipo de receptor 5-ht1a.
MXPA03009073A (es)	2004-02-17	Altavoz.
GB0101784D0 (en)	2001-03-07	Amplifier
GB2374477B (en)	2004-11-24	Low noise amplifiers
GB0109278D0 (en)	2001-05-30	Enzyme inhibitors
GB2381977B (en)	2005-03-30	Amplifiers
GB0110854D0 (en)	2002-03-27	Amplifier
GB0120882D0 (en)	2001-10-17	Amplifier
GB0116458D0 (en)	2001-08-29	Amplifier
AU2002314173A1 (en)	2003-03-03	Pyridazinone
GB0104691D0 (en)	2001-04-11	Enzyme inhibitor
ZA200301145B (en)	2003-08-27	Silencer.
GB0106564D0 (en)	2001-05-09	Enzyme inhibitors
GB0109145D0 (en)	2001-05-30	Enzyme inhibitors
GB0101537D0 (en)	2001-03-07	Enzyme inhibitors
GB0102194D0 (en)	2001-03-14	Enzyme inhibitors

Legal Events

Date	Code	Title	Description
2009-09-11	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20090131